

Human DNA Vaccine Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Route of Administration (Intramuscular, Subcutaneous, Intradermal, Others), By Application (Oncology, Tuberculosis, HIV, Others), By End User (Hospitals & Clinics, Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others), By Region & Competition, 2020-2030F

Market Report | 2025-05-23 | 180 pages | TechSci Research

AVAILABLE LICENSES:

- Single User License \$4500.00
- Multi-User License \$5500.00
- Custom Research License \$8000.00

Report description:

Market Overview

The Global Human DNA Vaccine Market was valued at USD 345.44 million in 2024 and is projected to reach USD 523.99 million by 2030, growing at a CAGR of 7.15%. This market is undergoing robust growth fueled by advancements in genetic engineering, increased investment in the healthcare sector, and heightened demand for cutting-edge therapeutic and preventive solutions. DNA vaccines operate through the direct delivery of engineered plasmid DNA encoding specific antigens, stimulating precise immune responses. These vaccines stand out for their enhanced safety profile, shorter development timelines, and adaptability across a broad spectrum of diseases. Positioned within the dynamic vaccine industry, the DNA vaccine market is poised for rapid evolution driven by continuous technological breakthroughs, expanded clinical applications, and heightened global health priorities. Companies that align with regulatory trends and innovate in delivery technologies are expected to gain significant competitive advantages.

Key Market Drivers

Rising Prevalence of Infectious and Chronic Diseases

The escalating occurrence of both infectious and chronic diseases is a critical driver for the Global Human DNA Vaccine Market. In 2021, approximately 18 million people died prematurely from noncommunicable diseases (NCDs), with 82% of these deaths occurring in low- and middle-income countries (LMICs), underscoring the disproportionate impact on economically disadvantaged regions. Furthermore, LMICs accounted for 73% of all NCD-related deaths globally. This significant health burden amplifies the

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott-international.com

www.scott-international.com

need for innovative vaccination approaches like DNA vaccines, which are gaining momentum due to their unique benefits. Notably, in 2023, about 1.3 million people contracted HIV worldwide, a 39% reduction in new cases from 2010, indicating a global infection rate of 0.17 per 1,000 uninfected individuals. As diseases such as HIV, Hepatitis, Tuberculosis, HPV, COVID-19, Zika, and Ebola continue to challenge public health systems, DNA vaccines offer scalable, adaptable, and long-lasting immune protection-traits that are increasingly in demand globally.

Key Market Challenges

Limited Clinical Success and Regulatory Approvals

Despite encouraging outcomes in preclinical stages, human DNA vaccines face challenges in achieving strong clinical efficacy. A primary obstacle is their lower immunogenicity in humans when compared to traditional vaccine types, which often leads to suboptimal immune responses in clinical settings-especially when conventional administration methods are used. Consequently, regulatory approval for human use remains limited, with most authorizations to date focused on veterinary applications. Although the pandemic has accelerated interest in DNA vaccines for humans, regulatory bodies continue to require comprehensive data on long-term safety and efficacy. These stringent and often uncertain regulatory demands present a substantial hurdle, particularly for smaller biotech firms, thereby slowing commercial progress and investment in the field.

Key Market Trends

Shift Toward Platform-Based Vaccine Technologies

The vaccine sector is witnessing a strong trend toward platform-based technologies, which leverage a unified system for developing multiple vaccines. DNA vaccine platforms exemplify this model. By standardizing delivery mechanisms, production processes, and clinical trial protocols, these platforms significantly cut down on development time and costs. They also enable rapid responses to emergent health threats, supporting quicker vaccine rollouts. Pharmaceutical companies and investors are increasingly attracted to this scalable framework, which not only fosters efficient product pipelines but also strengthens pandemic preparedness strategies. These systems support diverse disease applications, enhance public-private collaborations, and draw funding from global health stakeholders.

Key Market Players

- BOEHRINGER INGELHEIM GmbH (Merial)
- ELI-LILLY (Novartis Animal Health)
- Gene One Life Science
- GEOVAX LABS, INC
- Inovio Pharmaceuticals (VGX Animal Health)
- Genexine, Inc.
- VIATRIS INC. (Rottapharm Biotech)
- Takara Holdings (Takara Bio)
- ZOETIS INC. (Fort dodge Animal Health)
- Zydus Lifesciences Limited

Report Scope:

In this report, the Global Human DNA Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

- Human DNA Vaccine Market, By Route of Administration:

- o Intramuscular
- o Subcutaneous
- o Intradermal
- o Others

- Human DNA Vaccine Market, By Application:

- o Oncology
- o Tuberculosis
- o HIV
- o Others

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Human DNA Vaccine Market, By End User:
 - o Hospitals & Clinics
 - o Biotechnology & Pharmaceutical Companies
 - o Academic & Research Institutions
 - o Others

- Human DNA Vaccine Market, By Region:

- o North America
 - United States
 - Canada
 - Mexico
- o Europe
 - France
 - United Kingdom
 - Italy
 - Germany
 - Spain
- o Asia-Pacific
 - China
 - India
 - Japan
 - Australia
 - South Korea
- o South America
 - Brazil
 - Argentina
 - Colombia
- o Middle East & Africa
 - South Africa
 - Saudi Arabia
 - UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Human DNA Vaccine Market.

Available Customizations:

Global Human DNA Vaccine market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

- Detailed analysis and profiling of additional market players (up to five).

Table of Contents:

1. Product Overview
 - 1.1. Market Definition
 - 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations
2. Research Methodology

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
 - 3.1. Overview of the Market
 - 3.2. Overview of Key Market Segmentations
 - 3.3. Overview of Key Market Players
 - 3.4. Overview of Key Regions/Countries
 - 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Human DNA Vaccine Market Outlook
 - 5.1. Market Size & Forecast
 - 5.1.1. By Value
 - 5.2. Market Share & Forecast
 - 5.2.1. By Route of Administration (Intramuscular, Subcutaneous, Intradermal, Others)
 - 5.2.2. By Application (Oncology, Tuberculosis, HIV, Others)
 - 5.2.3. By End User (Hospitals & Clinics, Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
 - 5.2.4. By Region
 - 5.2.5. By Company (2024)
 - 5.3. Market Map
6. North America Human DNA Vaccine Market Outlook
 - 6.1. Market Size & Forecast
 - 6.1.1. By Value
 - 6.2. Market Share & Forecast
 - 6.2.1. By Route of Administration
 - 6.2.2. By Application
 - 6.2.3. By End User
 - 6.2.4. By Country
 - 6.3. North America: Country Analysis
 - 6.3.1. United States Human DNA Vaccine Market Outlook
 - 6.3.1.1. Market Size & Forecast
 - 6.3.1.1.1. By Value
 - 6.3.1.2. Market Share & Forecast
 - 6.3.1.2.1. By Route of Administration
 - 6.3.1.2.2. By Application
 - 6.3.1.2.3. By End User
 - 6.3.2. Canada Human DNA Vaccine Market Outlook
 - 6.3.2.1. Market Size & Forecast
 - 6.3.2.1.1. By Value
 - 6.3.2.2. Market Share & Forecast
 - 6.3.2.2.1. By Route of Administration
 - 6.3.2.2.2. By Application
 - 6.3.2.2.3. By End User

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.3.3. Mexico Human DNA Vaccine Market Outlook
 - 6.3.3.1. Market Size & Forecast
 - 6.3.3.1.1. By Value
 - 6.3.3.2. Market Share & Forecast
 - 6.3.3.2.1. By Route of Administration
 - 6.3.3.2.2. By Application
 - 6.3.3.2.3. By End User
- 7. Europe Human DNA Vaccine Market Outlook
 - 7.1. Market Size & Forecast
 - 7.1.1. By Value
 - 7.2. Market Share & Forecast
 - 7.2.1. By Route of Administration
 - 7.2.2. By Application
 - 7.2.3. By End User
 - 7.2.4. By Country
 - 7.3. Europe: Country Analysis
 - 7.3.1. Germany Human DNA Vaccine Market Outlook
 - 7.3.1.1. Market Size & Forecast
 - 7.3.1.1.1. By Value
 - 7.3.1.2. Market Share & Forecast
 - 7.3.1.2.1. By Route of Administration
 - 7.3.1.2.2. By Application
 - 7.3.1.2.3. By End User
 - 7.3.2. United Kingdom Human DNA Vaccine Market Outlook
 - 7.3.2.1. Market Size & Forecast
 - 7.3.2.1.1. By Value
 - 7.3.2.2. Market Share & Forecast
 - 7.3.2.2.1. By Route of Administration
 - 7.3.2.2.2. By Application
 - 7.3.2.2.3. By End User
 - 7.3.3. Italy Human DNA Vaccine Market Outlook
 - 7.3.3.1. Market Size & Forecast
 - 7.3.3.1.1. By Value
 - 7.3.3.2. Market Share & Forecast
 - 7.3.3.2.1. By Route of Administration
 - 7.3.3.2.2. By Application
 - 7.3.3.2.3. By End User
 - 7.3.4. France Human DNA Vaccine Market Outlook
 - 7.3.4.1. Market Size & Forecast
 - 7.3.4.1.1. By Value
 - 7.3.4.2. Market Share & Forecast
 - 7.3.4.2.1. By Route of Administration
 - 7.3.4.2.2. By Application
 - 7.3.4.2.3. By End User
 - 7.3.5. Spain Human DNA Vaccine Market Outlook
 - 7.3.5.1. Market Size & Forecast
 - 7.3.5.1.1. By Value

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.3.5.2. Market Share & Forecast
 - 7.3.5.2.1. By Route of Administration
 - 7.3.5.2.2. By Application
 - 7.3.5.2.3. By End User
- 8. Asia-Pacific Human DNA Vaccine Market Outlook
 - 8.1. Market Size & Forecast
 - 8.1.1. By Value
 - 8.2. Market Share & Forecast
 - 8.2.1. By Route of Administration
 - 8.2.2. By Application
 - 8.2.3. By End User
 - 8.2.4. By Country
 - 8.3. Asia-Pacific: Country Analysis
 - 8.3.1. China Human DNA Vaccine Market Outlook
 - 8.3.1.1. Market Size & Forecast
 - 8.3.1.1.1. By Value
 - 8.3.1.2. Market Share & Forecast
 - 8.3.1.2.1. By Route of Administration
 - 8.3.1.2.2. By Application
 - 8.3.1.2.3. By End User
 - 8.3.2. India Human DNA Vaccine Market Outlook
 - 8.3.2.1. Market Size & Forecast
 - 8.3.2.1.1. By Value
 - 8.3.2.2. Market Share & Forecast
 - 8.3.2.2.1. By Route of Administration
 - 8.3.2.2.2. By Application
 - 8.3.2.2.3. By End User
 - 8.3.3. Japan Human DNA Vaccine Market Outlook
 - 8.3.3.1. Market Size & Forecast
 - 8.3.3.1.1. By Value
 - 8.3.3.2. Market Share & Forecast
 - 8.3.3.2.1. By Route of Administration
 - 8.3.3.2.2. By Application
 - 8.3.3.2.3. By End User
 - 8.3.4. South Korea Human DNA Vaccine Market Outlook
 - 8.3.4.1. Market Size & Forecast
 - 8.3.4.1.1. By Value
 - 8.3.4.2. Market Share & Forecast
 - 8.3.4.2.1. By Route of Administration
 - 8.3.4.2.2. By Application
 - 8.3.4.2.3. By End User
 - 8.3.5. Australia Human DNA Vaccine Market Outlook
 - 8.3.5.1. Market Size & Forecast
 - 8.3.5.1.1. By Value
 - 8.3.5.2. Market Share & Forecast
 - 8.3.5.2.1. By Route of Administration
 - 8.3.5.2.2. By Application

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.3.5.2.3. By End User
- 9. South America Human DNA Vaccine Market Outlook
 - 9.1. Market Size & Forecast
 - 9.1.1. By Value
 - 9.2. Market Share & Forecast
 - 9.2.1. By Route of Administration
 - 9.2.2. By Application
 - 9.2.3. By End User
 - 9.2.4. By Country
 - 9.3. South America: Country Analysis
 - 9.3.1. Brazil Human DNA Vaccine Market Outlook
 - 9.3.1.1. Market Size & Forecast
 - 9.3.1.1.1. By Value
 - 9.3.1.2. Market Share & Forecast
 - 9.3.1.2.1. By Route of Administration
 - 9.3.1.2.2. By Application
 - 9.3.1.2.3. By End User
 - 9.3.2. Argentina Human DNA Vaccine Market Outlook
 - 9.3.2.1. Market Size & Forecast
 - 9.3.2.1.1. By Value
 - 9.3.2.2. Market Share & Forecast
 - 9.3.2.2.1. By Route of Administration
 - 9.3.2.2.2. By Application
 - 9.3.2.2.3. By End User
 - 9.3.3. Colombia Human DNA Vaccine Market Outlook
 - 9.3.3.1. Market Size & Forecast
 - 9.3.3.1.1. By Value
 - 9.3.3.2. Market Share & Forecast
 - 9.3.3.2.1. By Route of Administration
 - 9.3.3.2.2. By Application
 - 9.3.3.2.3. By End User
- 10. Middle East and Africa Human DNA Vaccine Market Outlook
 - 10.1. Market Size & Forecast
 - 10.1.1. By Value
 - 10.2. Market Share & Forecast
 - 10.2.1. By Route of Administration
 - 10.2.2. By Application
 - 10.2.3. By End User
 - 10.2.4. By Country
 - 10.3. MEA: Country Analysis
 - 10.3.1. South Africa Human DNA Vaccine Market Outlook
 - 10.3.1.1. Market Size & Forecast
 - 10.3.1.1.1. By Value
 - 10.3.1.2. Market Share & Forecast
 - 10.3.1.2.1. By Route of Administration
 - 10.3.1.2.2. By Application
 - 10.3.1.2.3. By End User

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.3.2. Saudi Arabia Human DNA Vaccine Market Outlook
 - 10.3.2.1. Market Size & Forecast
 - 10.3.2.1.1. By Value
 - 10.3.2.2. Market Share & Forecast
 - 10.3.2.2.1. By Route of Administration
 - 10.3.2.2.2. By Application
 - 10.3.2.2.3. By End User
- 10.3.3. UAE Human DNA Vaccine Market Outlook
 - 10.3.3.1. Market Size & Forecast
 - 10.3.3.1.1. By Value
 - 10.3.3.2. Market Share & Forecast
 - 10.3.3.2.1. By Route of Administration
 - 10.3.3.2.2. By Application
 - 10.3.3.2.3. By End User
- 11. Market Dynamics
 - 11.1. Drivers
 - 11.2. Challenges
- 12. Market Trends & Developments
 - 12.1. Recent Developments
 - 12.2. Product Launches
 - 12.3. Mergers & Acquisitions
- 13. Global Human DNA Vaccine Market: SWOT Analysis
- 14. Competitive Landscape
 - 14.1. BOEHRINGER INGELHEIM GmbH (Merial)
 - 14.1.1. Business Overview
 - 14.1.2. Product & Service Offerings
 - 14.1.3. Recent Developments
 - 14.1.4. Financials (If Listed)
 - 14.1.5. Key Personnel
 - 14.1.6. SWOT Analysis
 - 14.2. ELI-LILLY (Novartis Animal Health)
 - 14.3. Gene One Life Science
 - 14.4. GEOVAX LABS, INC
 - 14.5. Inovio Pharmaceuticals (VGX Animal Health)
 - 14.6. Genexine, Inc.
 - 14.7. VIATRIS INC. (Rottapharm Biotech)
 - 14.8. Takara Holdings (Takara Bio)
 - 14.9. ZOETIS INC. (Fort dodge Animal Health)
 - 14.10. Zydus Lifesciences Limited
- 15. Strategic Recommendations
- 16. About Us & Disclaimer

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Human DNA Vaccine Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Route of Administration (Intramuscular, Subcutaneous, Intradermal, Others), By Application (Oncology, Tuberculosis, HIV, Others), By End User (Hospitals & Clinics, Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others), By Region & Competition, 2020-2030F

Market Report | 2025-05-23 | 180 pages | TechSci Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4500.00
	Multi-User License	\$5500.00
	Custom Research License	\$8000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-10"/>
		Signature	<input type="text"/>